Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPension (IS)Profit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Harvard Bioscience (HBIO) Restructuring Costs (2016 - 2025)

Harvard Bioscience (HBIO) has disclosed Restructuring Costs for 11 consecutive years, with $48000.0 as the latest value for Q3 2025.

  • Quarterly Restructuring Costs fell 73.18% to $48000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $350000.0 through Sep 2025, down 39.13% year-over-year, with the annual reading at -$233000.0 for FY2022, 177.67% down from the prior year.
  • Restructuring Costs for Q3 2025 was $48000.0 at Harvard Bioscience, up from $30000.0 in the prior quarter.
  • The five-year high for Restructuring Costs was $5.2 million in Q1 2022, with the low at -$4.9 million in Q2 2022.
  • Average Restructuring Costs over 4 years is $88111.1, with a median of $93000.0 recorded in 2025.
  • Peak annual rise in Restructuring Costs hit 73.18% in 2025, while the deepest fall reached 92.42% in 2025.
  • Over 4 years, Restructuring Costs stood at $300000.0 in 2021, then tumbled by 281.33% to -$544000.0 in 2022, then soared by 132.9% to $179000.0 in 2024, then plummeted by 73.18% to $48000.0 in 2025.
  • According to Business Quant data, Restructuring Costs over the past three periods came in at $48000.0, $30000.0, and $93000.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.